Camille Locht, Ph.D. serves as a member of ILiAD’s Scientific Advisory Board. Dr. Locht currently holds a position as Research Director at the French National Institute of Health and Medical Research (Inserm) and has been the founding director of the Center for Infection and Immunity of Lille at the Institut Pasteur de Lille in France. He obtained his PhD at the Catholic University of Leuven in Belgium in 1984. After 3 post-doctoral years at the National Institute of Allergy and Infectious Disease (USA), where he cloned the pertussis toxin genes, he joined SmithKline – Beecham (now GSK) to help develop acellular pertussis vaccines. In 1989 he was appointed as laboratory chief at the Institut Pasteur de Lille, where he has been the Scientific Director from 2003 to 2013. His research interest is in the molecular pathogenesis of respiratory infections, particularly pertussis and tuberculosis, with the long-term aim to develop new vaccines against both diseases. A very powerful molecular typing system for mycobacteria, invented in his laboratory has already reached the market, and the live attenuated nasal pertussis vaccine BPZE1 was developed in his laboratory has now completed phase 2 clinical trials. He has authored more than 350 international publications and book chapters, 20 patents, has edited a sourcebook on Bordetella Molecular Microbiology and has obtained several research awards in France and abroad. He has recently been appointed as the task force leader of the French initiative of anti-COVID-19 vaccine research.